Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical PipelinePRNewsWire • 03/01/22
Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 11/10/21
Pulmatrix, Inc. (PULM) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 11/04/21
Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 08/10/21
Earnings Preview: Pulmatrix, Inc. (PULM) Q2 Earnings Expected to DeclineZacks Investment Research • 07/30/21
Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business UpdatePRNewsWire • 05/11/21
Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute MigrainePRNewsWire • 04/15/21
Corrected: Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor PortfolioPRNewsWire • 04/12/21
Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor PortfolioPRNewsWire • 04/12/21
Pulmatrix Announces $40 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesPRNewsWire • 02/11/21